
TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity
Keywords: ادجوانت، یاور; RSV; Toll-like receptors; Eosinophil; Adjuvant; Pathogenesis; Immunization; Pathology